.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
EMPA-KIDNEY broadened the evidence for SGLT2 inhibition by enrolling patients with chronic kidney disease across a wide range of diabetes status and eGFR. Empagliflozin reduced the risk of kidney disease progression or cardiovascular death compared with placebo, supporting a kidney-protective effect beyond glucose lowering. The study is especially relevant to general physicians because CKD is frequently detected late and often coexists with diabetes and hypertension. For practice, the major opportunity is earlier identification using eGFR and urine albumin testing, followed by risk-based therapy and monitoring. SGLT2 inhibitors should be integrated with renin–angiotensin system blockade where indicated and with appropriate blood-pressure, glycemic and cardiovascular management. Volume status and renal function need review around initiation and during acute illness. EMPA-KIDNEY strengthens the concept that nephroprotection is a central component of cardiometabolic medicine rather than a specialist-only concern.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
EMPA-KIDNEY broadened the evidence for SGLT2 inhibition by enrolling patients with chronic kidney disease across a wide range of diabetes status and eGFR. Empagliflozin reduced the risk of kidney disease progression or cardiovascular death compared with placebo, supporting a kidney-protective effect beyond glucose lowering. The study is especially relevant to general physicians because CKD is frequently detected late and often coexists with diabetes and hypertension. For practice, the major opportunity is earlier identification using eGFR and urine albumin testing, followed by risk-based therapy and monitoring. SGLT2 inhibitors should be integrated with renin–angiotensin system blockade where indicated and with appropriate blood-pressure, glycemic and cardiovascular management. Volume status and renal function need review around initiation and during acute illness. EMPA-KIDNEY strengthens the concept that nephroprotection is a central component of cardiometabolic medicine rather than a specialist-only concern.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
